Ironwood Pharmaceuticals, Inc. — 2017 Form 10-K
Business context and reporting period. Annual report for the fiscal year ended December 31, 2017; quarterly figures below are for the fourth quarter. Ironwood is a commercial biotechnology company whose revenue is principally tied to LINZESS, commercialized in the U.S. with Allergan. It also launched DUZALLO in 2017 and sells ZURAMPIC, while funding clinical-stage programs including IW-3718, praliciguat and IW-1701.
Financial performance and liquidity
Amounts are in U.S. dollars; annual figures are for fiscal years ended December 31.
| Metric | 2017 | 2016 |
|---|---|---|
| Total revenue | $298.3 million | $274.0 million |
| Operating loss | $77.4 million | $51.9 million |
| Net loss | $116.9 million | $81.7 million |
| Net loss per share | $0.78 | $0.56 |
| Operating cash flow | $(99.6) million | $(25.4) million |
| Cash, cash equivalents and available-for-sale securities | $221.4 million | $305.2 million |
| Working capital, excluding deferred revenue | $245.6 million | $289.1 million |
- Revenue grew 9%. Collaborative-arrangements revenue was $265.5 million, including $256.2 million from Ironwood’s share of U.S. LINZESS collaboration results; API sales were $29.7 million and net lesinurad product revenue was $3.1 million.
- Research and development expense rose 6% to $148.2 million; selling, general and administrative expense increased 35% to $233.1 million, primarily reflecting commercialization investment for lesinurad.
- Reported expenses included a $31.3 million noncash gain from remeasurement of contingent consideration, following lower projected DUZALLO and ZURAMPIC revenue. Despite that gain, annual net loss widened.
- Fourth-quarter revenue was $94.2 million and net income was $12.1 million, compared with revenue of $87.5 million and a net loss of $13.5 million in Q4 2016. The 2017 quarter included a substantial contingent-consideration gain; quarterly results are not necessarily indicative of future results.
- Cash, cash equivalents and available-for-sale securities declined $83.8 million during 2017. Cash used in investing activities was $151.5 million, largely reflecting securities purchases and maturities; cash provided by financing activities was $19.8 million.
- At year-end, reported total indebtedness was approximately $485.7 million. Principal included $335.7 million of 2.25% convertible notes due 2022 and $150.0 million of 8.375% notes due 2026. The 2026 notes begin quarterly payments tied to U.S. LINZESS sales in March 2019. The notes are subject to different terms and security arrangements.
- Management stated that available cash was expected to fund projected operating needs for at least the 12 months following issuance of the financial statements; this is an estimate subject to operating and commercial risks.
Material changes and developments
- Total revenue increased $24.3 million year over year, driven principally by higher U.S. LINZESS collaboration revenue and Japan-related linaclotide API shipments. U.S. LINZESS collaboration revenue rose to $256.2 million from $217.7 million.
- Higher commercialization spending, particularly for the lesinurad products, contributed to increased SG&A and a larger operating loss. R&D spending also increased, with greater investment in early-stage pipeline candidates.
- DUZALLO received FDA approval in August and launched in October 2017. LINZESS 72 mcg for adult CIC was approved in January and became available in March.
- Ironwood issued $150 million of 2026 notes and redeemed its 11% PhaRMA notes in January 2017. Cash payments included a $15 million AstraZeneca milestone for DUZALLO approval.
- Lesinurad product revenue recognition changed from sell-through to sell-in in Q4 2017 as Ironwood determined it could reasonably estimate returns and other adjustments; the transition added approximately $0.9 million to revenue.
Outlook, risks and unusual items
- Management did not provide numerical revenue or earnings guidance. Its stated objective is to become cash-flow positive, but it has not achieved positive operating cash flow and cannot predict when, or whether, profitability will be reached.
- In January 2018, Ironwood began testing a different lesinurad marketing mix and reducing investment in the franchise. It planned to cut approximately 60 field-based positions, with estimated one-time severance and benefit charges of $2.3–$2.8 million in Q1 2018.
- Management reported positive top-line Phase IIb data for IW-3718 and believed the findings supported potential advancement to Phase III. Clinical outcomes, regulatory approval and commercialization remain uncertain.
- LINZESS is a major revenue concentration: the filing reports 89% of 2017 revenue from the U.S. and 11% from outside the U.S.; the Allergan North America relationship accounted for 88% of revenue-recognition concentration in the customer disclosure. Ironwood depends on partner performance and estimates, including Allergan’s reporting of U.S. sales and costs.
- Risks include commercial adoption and reimbursement, competition, boxed warnings and post-marketing safety obligations for LINZESS and lesinurad, and reliance on third parties for manufacturing. Ironwood relies exclusively on AstraZeneca for commercial lesinurad supply.
- Generic manufacturers challenged LINZESS patents; litigation remained pending. A January 2018 settlement provides one generic manufacturer a license to launch from February 1, 2031, subject to FDA approval and specified exceptions. The filing notes a 2019 trial schedule for other litigants.
- Lesinurad intangible assets totaled $159.9 million at year-end and depend on projected product cash flows. Lower forecasts already reduced the contingent-consideration liability; further commercial underperformance could trigger an impairment.
- The independent auditor gave an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded controls were effective at year-end.
Important facts for investors to verify
- Whether LINZESS U.S. sales, collaboration profit share and related cash receipts support operating costs and debt service.
- Actual uptake, net pricing, reimbursement, returns and channel inventory for ZURAMPIC and DUZALLO, and the results of the 2018 lesinurad test markets.
- Progress and costs of the required lesinurad renal and cardiovascular safety study, and continued dependence on AstraZeneca for product supply.
- LINZESS generic litigation outcomes, the terms and contingencies of the 2031 settlement, and the effect of any additional settlements or patent decisions.
- Cash burn, debt obligations and covenants, including the 2026 notes’ sales-linked payments beginning in 2019 and the 2022 convertible notes’ maturity and conversion terms.
- Whether changes in commercial forecasts require impairment of lesinurad intangible assets or further adjustments to contingent consideration.